Compulsory Licensing
Contents |
Internet Workshop
Compulsory Licensing: current hot spots
Tuesday 20 Feb, 7:30pm
To be held using Paltalk internet software: see the Paltalk website to download.
Program
The workshop will provide an opportunity to hear about and discuss:
- compulsory licensing and where it stands now (Sharon)
- report of WHO Commission on IPRs and Health (David)
- current disputes over IPRs in India (Upendra) Novartis_India_Upendra_2007.ppt
- current disputes over IPRs in Thailand (Gillian).
Convenor: David Legge
The presentations will be brief and there will be adequate time for discussion. The workshop will not go on for more than one hour.
Technical
This workshop will be conducted via the internet in real time voice. The platform is PalTalk [1]
You will need a headset with earphones plus boom microphone (less than $30 at any electronics computer stuff shop). You need a computer (PC) with Win 2000 or higher and 128 MB RAM and a sound card.
We ask those who are thinking of coming to let me as convenor know what their PT ID is so that they can be invited into the room.
For more information email david[at]phmoz.org
Resources
Facts about compulsory licensing
WTO documents give a good overview of compulsory licensing and the key dates and documents: Fact Sheet Sept 2006 PDF file
Technical Note on pharmaceutical patents and the TRIPS agreement Web link
MSF documents are quite illuminating in how this fits into practical usage: PDF file, Web link
Report of WHO Commission on Intellectual Property Rights, Innovation and Public Health
Web link
Chapter six: Towards a sustainable plan to promote innovation and access
PDF file
News articles
India: Former Swiss President joins chorus against Novartis' patent challenge
15 February 2007:
More prominent figures have joined the chorus of over 300,000 people worldwide voicing concerns about Novartis’ legal challenge against the Indian government and its impact on access to essential medicines across the globe.
Read full article
WHO DG regrets her reported remarks on Thai compulsory licenses
15 February 2007: The WHO Director General Dr. Margaret Chan, has sent a letter to Thailand's Health Minister expressing regret for the embarrassment caused to his government by remarks she was reported to have made in Bangkok that were critical of the compulsory licenses granted by the government for three medicines.
Read full article
Stephen Lewis Criticises Margaret Chan
4 Feb 2007: Stephen Lewis, former UN Special Envoy for HIV/AIDS in Africa, calls for World Health Organization director Margaret Chan to reverse her support of drug companies over governments trying to provide medicines for their peoples. His remarks were recorded at the Global Justice student conference in Washington, DC, on February 4.
Video [2]
Fight AIDS [3]
WHO Chief's Stand on Generic Drugs Slammed
BANGKOK, Feb 2 (IPS) - Civil society and humanitarian groups slammed the new head of the World Health Organisation (WHO), on the sidelines of a meeting here, after she appeared to favour the interests of pharmaceutical giants over the plight of the sick and the poor in the developing world.
Full article available from IPS: [4]
Thailand approves copycat drugs
January 30, 2007: THAILAND'S army appointed government said today it had approved a cheap, copycat heart disease drug, the first time a developing country has ignored an international patent for such a treatment.
Full article available from The Australian: [5]
Thailand throws down gauntlet to drug giants
30 Jan 2007: IN A precedent-setting challenge to global drug companies, Thailand has become the first developing country to issue a compulsory licence to manufacture a generic drug that is not AIDS related.
Follow link to Sydney Morning Herald article.
[6]]
Thailand Invokes WTO Rule To Sell Generics For HIV And Heart Disease Drugs
30 Jan 2007: Thailand has invoked a World Trade Organization (WTO) agreement on
intellectual property rights to allow the manufacture, purchase and sale
of generic versions of two drugs for heart disease and HIV/AIDS in the
country.
Full article available online here
US activists try to deliver coffin to Novartis over Indian patent case
29 Jan: WASHINGTON (AFP) - Non-governmental groups tried to deliver a mini coffin to Swiss pharmaceuticals giant Novartis to protest legal action aiming to overturn a ban on a drug patent application in India.
http://news.yahoo.com/s/afp/20070129/hl_afp/usindiapharmacompany_070129215623
WHO’s mandate on IPRs under US attack
12 Dec 2006: At the recent meeting of WHO’s international working group on public health, innovation and intellectual property, the US challenged WHO’s work on the impact of Intellectual Property Rights (IPRs).
Read full article here
Other information
Rep Waxman letter to Novartis on Indian legal challenge
Read the letter here
Open Letter to WHO/UNAIDS India re Margaret Chan's comments on Thai Compulsory License
Read the letter here
WHO DG Chan Shocking Views Criticised by NGOs (Martin Khor, 5 Feb 07)
Read a Comment from PHM member on Chan's visit to Bangkok re Thai Compulsory License
MSF Petition regarding Novartis
http://www.msf.org/petition_india/can_eng.html
Journal articles
Please note, you will need access to the New England Journal of Medicine to read these articles. Most university libraries will provide access on site if you do not have online access.
Thailand and the Compulsory Licensing of Efavirenz' Robert Steinbrook NEJM Volume 356:544-546
Of the many medicines for human immunodeficiency virus (HIV) infection, efavirenz, a nonnucleoside reverse-transcriptase inhibitor that became available in the late 1990s, is one of the most important. For the initial treatment of adults, the combination of efavirenz and two nucleoside reverse-transcriptase inhibitors "has become a standard-of-care comparator in clinical trials," according to Hammer et al.1 Moreover, efavirenz is available in a fixed-dose combination tablet with the nucleoside analogues emtricitabine and tenofovir; this tablet is taken only once a day. Efavirenz can cause birth defects when taken during the first trimester of pregnancy, so its use is restricted in . . . .
Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines Janice M. Mueller NEJM Volume 356:541-543
In August and September 2006, patients with cancer, lawyers for patient advocacy groups, and representatives of nongovernmental organizations (NGOs) converged on the offices of Novartis in Mumbai, India, to protest the company's efforts to obtain an Indian patent on Gleevec, the company's brand-name version of imatinib mesylate. Gleevec (spelled Glivec outside the United States) is used to treat chronic myeloid leukemia, and Novartis has patented the drug in 35 countries. The protesters also decried the drug's high price: Novartis sells it in India (where only 5% of people have private health insurance) for $26,000 per year; generic-drug manufacturers offer the drug at less than one tenth that price....
